The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease? - Wikidata - wikimedia - TriplyDB

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

http://www.wikidata.org/entity/Q33630562

about

The therapeutic potential of the endocannabinoid system for Alzheimer's disease.Acetylcholinesterase inhibitors: a patent review (2008 - present).Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics.

P2860

Q37997020-AC283B69-9B81-4962-990A-6D3A961D48F2 Q38024391-272E8942-3BEB-487D-A028-CA22E8019C09 Q38881147-69729567-7351-4F76-95B5-D67D946E4339

P2860

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

http://www.wikidata.org/entity/Q33630562

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

@ast

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

@en

type

label

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

@ast

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

@en

prefLabel

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

@ast

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

@en

P1433

Q33630562-94A14FAE-6371-426F-9752-78A80E31B007

P1476

Q33630562-BD3FC9AC-F61A-47F2-B886-D3350CE8A5C7

P2093

Q33630562-0BC3F106-0427-434A-BAFE-CED41135C2B4

Q33630562-3E79FED0-6E1C-4828-BA80-93CA50186E5E

Q33630562-4324C0AB-6758-4FF5-AA2C-8B688EE2EF10

Q33630562-5FC39113-695E-4F8F-B62E-420B6054A2BA

Q33630562-EA1BAB1B-C1E0-4E5A-A6F8-537651B796C3

P2860

Q33630562-2635BC92-341E-4554-93C4-3C57CA072600

Q33630562-36555E4F-C99C-481B-A4B1-AE873982881D

Q33630562-3B5D4A50-E0B5-4648-A66E-C210F6887CE4

Q33630562-3FED3F47-027C-4278-B414-5D6A33E38041

Q33630562-44D4050B-AE3E-4C16-B9F4-A310C0015734

Q33630562-4B025214-CDA1-416B-AEE7-B8D0758C1A5A

Q33630562-5C4C76F1-4496-4936-94C5-0746FE39CBEC

Q33630562-5D71AC91-FB0D-495D-8F5C-60A206C3D8BE

Q33630562-5DC96D55-79F1-4E27-92A0-BF4A782E0BB9

Q33630562-5FF78FC9-CC65-4AE1-95E6-1C35078F8D8A

P304

Q33630562-9C963FF0-5FDD-4521-97CE-77A60921CE34

P31

Q33630562-E575FCA8-8851-4CED-83FD-6D9D0E6E8238

P356

Q33630562-A21900A2-1316-4437-B04A-879F2293214D

P433

Q33630562-FDAE39A3-B2A5-47EE-A6E9-617EAE48B0B0

P478

Q33630562-2E8AA161-3C9C-4558-9D83-9A1C031F8F9D

P50

Q33630562-D1C02135-8F4C-49DE-92B1-F43F3BF3645A

Q33630562-D81C96C4-CD1B-4E5D-832E-597331CFEE4F

Q33630562-DCC4E4DD-A265-48F9-BCEE-0423ABD9D4C4

P577

Q33630562-FCD14E41-D607-4B7A-AAAA-C7F148DD0951

P5875

Q33630562-112F7DC6-AA98-4821-B574-643040EE336B

P698

Q33630562-D402FD30-E66C-4CBB-8A84-5873699BFBDF

P921

Q33630562-7DFCE78C-2333-476E-BEF6-CD7C9F7FB1D5

P932

Q33630562-08145581-D1C8-467F-A412-BCDEDF39F4E9

P356

P1433

ACS Medicinal Chemistry Letters

P1476

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

@en

P2093

Alessandra Bisi

http://www.w3.org/2001/XMLSchema#string

Alessia Ligresti

http://www.w3.org/2001/XMLSchema#string

Angela Rampa

http://www.w3.org/2001/XMLSchema#string

Federica Belluti

http://www.w3.org/2001/XMLSchema#string

Silvia Gobbi

http://www.w3.org/2001/XMLSchema#string

P2860

A new and rapid colorimetric determination of acetylcholinesterase activity

Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains

Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent

Microglia-mediated neurotoxicity: uncovering the molecular mechanisms

Neurobiology of butyrylcholinesterase.

An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease.

Cholinergic function and Alzheimer's disease.

Designed multiple ligands. An emerging drug discovery paradigm.

P304

182-186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ML200313P

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Vincenzo Di Marzo

Manuela Bartolini

Vincenza Andrisano

P577

2012-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231712196

http://www.w3.org/2001/XMLSchema#string

P698

24900454

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4025825

http://www.w3.org/2001/XMLSchema#string